

Flt-1/VEGFR1 Antibody

Datasheet

For Research Use Only

Description	Catalog No.	Size
Flt-1/VEGFR1 Concentrate	FP-A082-01	0.1 ml
Flt-1/VEGFR1 Concentrate	FP-A082-10	1 ml
Flt-1/VEGFR1 Predilute	FP-A082-70	7 ml
Flt-1/VEGFR1 Predilute	FP-A082-250	25 ml

Description

Flt-1, also known as Fms Related Tyrosine Kinase 1 or VEGFR1 (Vascular Endothelial Growth Factor Receptor 1), is a tyrosine kinase involved in lymphangiogenesis, angiogenesis, and wound healing. It is present in endothelial cells, osteoblasts, placental trophoblasts, renal mesangial cells, and some hematopoietic stem cells. Anti-Flt-1/VEGFR1 is useful for identifying carcinomas of the larynx and esophagus.

Specifications

Clone	IHC577
Source	Mouse Monoclonal
Applications	IHC (P)
Formulation	Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide

IHC Procedure*

Positive Control Tissue	Angiosarcoma
Concetrated Dilution	1:50 – 1:200
Pretreatment	Perform heat-induced epitope retrieval (HIER) at pH 9 for 10 to 30 minutes
Incubation Time and Temp	10 to 30 minutes at room temperature
Detection	Refer to the detection system manual

*Result should confirmed by an established diagnostic procedure.

Result




Figure. Flt-1/VEGFR1 on Head and Neck Cancer



Storage and Handling

Must store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. To ensure proper stability and delivery of the antibody after each run, replace the cap and immediately place the bottle in a refrigerator in an upright position. Positive and negative controls should be simultaneously run with unknown specimens, as there are no conclusive characteristics to suggest instability of the antibody.

Precautions

The product is for research use only. Do not use for diagnosis purpose. Ensure proper handling procedures are used with all reagents. Always wear laboratory coats, disposable gloves, and other appropriate laboratory equipment when handling reagents. Do not ingest reagents, and avoid contact with eyes and mucous membranes. Wash eyes with copious amounts of water if contact occurs.

References

1. **Dahlman-Wright K**, et al. "International Union of Pharmacology. LXIV. Estrogen receptors." *Pharmacol Rev.* 2006 Dec;58(4):773-81.
2. **Levin ER**. "Integration of the extranuclear and nuclear actions of estrogen." *Mol Endocrinol.* 2005 Aug;19(8):1951-9. Epub 2005 Feb 10.
3. **Harris HA**, et al. "Evaluation of an estrogen receptor-beta agonist in animal models of human disease." *Endocrinology.* 2003 Oct;144(10):4241-9.

Technical Support

Contact FemtoPath Technical Support at +886232338585 or email to femtopath@hongjing.com.tw for questions regarding this product.